Peptides DB

Research-centric peptide and protocol reference hub

AOD-9604 vs Melanotan 1

Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team

AOD-9604: Research use — not FDA-approvedMelanotan 1: Research use — not FDA-approved

A data-driven comparison of AOD-9604 and Melanotan 1 (also searched as Melanotan 1 vs AOD-9604) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

AOD-9604 centers on metabolic, while Melanotan 1 leans toward skin. On indexed research, AOD-9604 is ahead (AOD-9604: 4 studies, Human evidence; Melanotan 1: 4, Preclinical). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • AOD-9604 is strongest for metabolic; Melanotan 1 for skin.
  • Evidence: AOD-9604 Human evidence (4 studies) vs Melanotan 1 Preclinical (4).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

HealingMuscleMetabolicNeuroSleepInflammationSkin
AOD-9604Melanotan 1

At a glance

AOD-9604Human evidence

Modified hGH Fragment | Fat Loss Peptide

Strongest: MetabolicStudies: 4Level: Well Studied
Melanotan 1Preclinical
Strongest: SkinStudies: 4Level:

AOD-9604 vs Melanotan 1: side-by-side

MetricAOD-9604Melanotan 1
ClassWeight Loss
Regulatory statusResearch use onlyResearch use only
Evidence gradeHuman evidencePreclinical
Studies indexed44
Research levelWell Studied
Strongest effectMetabolic & appetiteSkin & aesthetics
Healing & recovery3.02.0
Muscle & body comp0.00.0
Metabolic & appetite4.01.0
Neuro & mood0.03.0
Sleep & circadian0.00.0
Inflammation & immune0.02.0
Skin & aesthetics2.05.0

▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).

Mechanism & pharmacokinetics

PropertyAOD-9604Melanotan 1
MechanismModified hGH fragment (176–191)Melanocortin-receptor agonist
RouteSubcutaneous injection (research use)Subcutaneous injection (research use)

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is AOD-9604?

A GH-fragment–derived peptide primarily discussed for fat loss and body-composition change, sometimes with cartilage and joint-repair context.

Full AOD-9604 profile, mechanism & studies →

What is Melanotan 1?

### Melanotan 1 Summary Melanotan 1, also known as afamelanotide, is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH) that primarily acts as a melanocortin receptor agonist. It has been investigated for its potential applications in enhancing skin pigmentation and its role in various therapeutic contexts, including neuroprotection and cancer research.

Full Melanotan 1 profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingAOD-96043.0/5 effect signal
MetabolicAOD-96044.0/5 effect signal
NeuroMelanotan 13.0/5 effect signal
InflammationMelanotan 12.0/5 effect signal
SkinMelanotan 15.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack AOD-9604 and Melanotan 1?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

AOD-9604 vs Melanotan 1: side effects

AOD-9604

No community-reported effects logged yet.

Melanotan 1

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

AOD-9604 has 4 approved studies indexed (Human evidence), and Melanotan 1 has 4 (Preclinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is AOD-9604 or Melanotan 1 better?

It depends on your goal. AOD-9604 is strongest for metabolic; Melanotan 1 for skin. AOD-9604 has more indexed studies (4). See the goal-by-goal breakdown above.

Is AOD-9604 or Melanotan 1 better for weight loss?

AOD-9604 shows the stronger metabolic & appetite profile (4.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.

Which has more research, AOD-9604 or Melanotan 1?

AOD-9604 has 4 approved studies indexed (Human evidence); Melanotan 1 has 4 (Preclinical). Higher counts mean more to read, not proven superiority.

Can you stack AOD-9604 and Melanotan 1?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of AOD-9604 vs Melanotan 1?

AOD-9604: no community-reported effects logged yet. Melanotan 1: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is AOD-9604 or Melanotan 1 FDA-approved?

AOD-9604 is a research-use compound and is not FDA-approved. Melanotan 1 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is Melanotan 1 better than AOD-9604?

For skin, Melanotan 1 has the edge; for metabolic, AOD-9604 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

AOD-9604 and Melanotan 1 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.